Giovanni Di Perri

Giovanni Di Perri

Turin, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 371 publications

The multifaceted antiretroviral coverage provided by BIC/FTC/TAF: a pharmacokinetic/pharmacodynamic revisitation.

The multifaceted antiretroviral coverage provided by BIC/FTC/TAF: a pharmacokinetic/pharmacodynamic revisitation.

Journal: Le infezioni in medicina

Published: March 18, 2026

The cerebrospinal fluid virome in people with HIV: links to neuroinflammation and cognition.

The cerebrospinal fluid virome in people with HIV: links to neuroinflammation and cognition.

Journal: Frontiers in microbiology

Published: September 12, 2025

Extending follow-up visits in people with HIV (PWH) receiving bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) therapy: an expert opinion.

Extending follow-up visits in people with HIV (PWH) receiving bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) therapy: an expert opinion.

Journal: Le infezioni in medicina

Published: June 20, 2025

The Influence of Blood Brain Barrier Permeability on CSF-To-Serum Ratios of Neurobiomarkers in People With HIV.

The Influence of Blood Brain Barrier Permeability on CSF-To-Serum Ratios of Neurobiomarkers in People With HIV.

Journal: Journal of neurochemistry

Published: April 17, 2025

Full reservoirs and poor adherence: two cases of symptomatic HIV cerebrospinal fluid escape with tenofovir alafenamide/emtricitabine/bictegravir.

Full reservoirs and poor adherence: two cases of symptomatic HIV cerebrospinal fluid escape with tenofovir alafenamide/emtricitabine/bictegravir.

Journal: AIDS (London, England)

Published: March 11, 2025

The cerebrospinal fluid virome in people with HIV: links to neuroinflammation and cognition.

The cerebrospinal fluid virome in people with HIV: links to neuroinflammation and cognition.

Journal: bioRxiv : the preprint server for biology

Published: March 10, 2025

The Clinical Presentations of Patients With COVID-19 in the Omicron Era: Missed Opportunities in the Antiviral Treatment of SARS-CoV-2 Infections.

The Clinical Presentations of Patients With COVID-19 in the Omicron Era: Missed Opportunities in the Antiviral Treatment of SARS-CoV-2 Infections.

Journal: Journal of medical virology

Published: March 06, 2025

Effectiveness, safety, and patient-reported outcomes of bictegravir/emtricitabine/tenofovir alafenamide in routine clinical care in Italy: 12-Month results from the BICSTaR cohort.

Effectiveness, safety, and patient-reported outcomes of bictegravir/emtricitabine/tenofovir alafenamide in routine clinical care in Italy: 12-Month results from the BICSTaR cohort.

Journal: International journal of STD & AIDS

Published: January 08, 2025

Clinical Pharmacology of the Single Tablet Regimen Bictegravir/Emtricitabine/Tenofovir Alafenamide in the evolving era of antiretroviral therapies.

Clinical Pharmacology of the Single Tablet Regimen Bictegravir/Emtricitabine/Tenofovir Alafenamide in the evolving era of antiretroviral therapies.

Journal: The new microbiologica

Published: November 19, 2024

Factors Associated with HIV Viral Suppression in People Followed in an Outpatient Clinic in Angola During and After the COVID-19 Pandemic.

Factors Associated with HIV Viral Suppression in People Followed in an Outpatient Clinic in Angola During and After the COVID-19 Pandemic.

Journal: AIDS patient care and STDs

Published: October 04, 2024

How Antiretroviral Drug Concentrations Could Be Affected by Oxidative Stress, Physical Capacities and Genetics: A Focus on Dolutegravir Treated Male PLWH.

How Antiretroviral Drug Concentrations Could Be Affected by Oxidative Stress, Physical Capacities and Genetics: A Focus on Dolutegravir Treated Male PLWH.

Journal: Antioxidants (Basel, Switzerland)

Published: September 27, 2024

Symptomatic and Asymptomatic Neurocognitive Impairment, ART Adherence and HIV Control: A 4-Year Observational Study.

Symptomatic and Asymptomatic Neurocognitive Impairment, ART Adherence and HIV Control: A 4-Year Observational Study.

Journal: AIDS and behavior

Published: June 27, 2024

Showing 1-12 of 371

Last Updated: 09/26/2026